

CSD/BSE&NSE/PR/2026-2027

June 12, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

.....

With reference to above subject, please find enclosed News Release of our company titled **“Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at the SLEEP-2026 Annual Meeting being held at Baltimore, USA”**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

K. Sangeetha Laxmi
Company Secretary

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

News Release

Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at the SLEEP-2026 Annual Meeting being held at Baltimore, USA.

Hyderabad, India (12-June-2026) - Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders today announced that it will present three posters at SLEEP-2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC (APSS) being held at Baltimore, USA during June 14-17, 2026.

The APSS is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The SLEEP meeting is the premier clinical and scientific meeting focused on sleep medicine, sleep and circadian research, and sleep health. SLEEP 2026 will feature more than 140 exhibits, 1,500 research abstract presentations, and 5,000 attendees, speakers, and exhibitors.

The presentations will showcase the clinical advancement of **Samelisant (SUVN-G3031)**, including positive Phase 2 efficacy data in excessive daytime sleepiness (EDS), the rationale and design of a Phase 2 study for cataplexy in Type 1 narcolepsy, and the Phase 3 development strategy for Samelisant in patients with narcolepsy (AWAKE study).

Poster Presentations:

- Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness in Patients with Narcolepsy: Phase-2 Results (**15 June, 2026; Poster # 374**)
- Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients with Type 1 Narcolepsy (**15 June, 2026; Poster # 368**)
- Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness in Patients with Narcolepsy (**16 June, 2026; Poster # 332**)

Members of Suven scientific team scheduled several meetings at Suven Exhibit booth # 1034, with Phase-3 study Principle Investigators, KOLs and potential partnering companies.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com



About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase 2a study completed; Double blind randomized Placebo controlled Phase-2b study recruitment completed); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/ services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com